39762 Investors following Ranbaxy Labs. Share this News with them.
0
Like this story, share it with millions of investors on M3
Ranbaxy Labs Q1CY08 net sales seen at Rs 1731 crore
Ranbaxy Labs is to announce its Q1CY08 numbers. According to CNBC-TV18 estimates, the company is expected to post 9% growth in its consolidated net profit of Rs 139 crore as against Rs 127.60 crore YoY.
Ranbaxy Labs is to announce its Q1CY08 numbers. According to CNBC-TV18 estimates, the company is expected to post 9% growth in its consolidated net profit of Rs 139 crore as against Rs 127.60 crore YoY.
Net sales is seen going up 11% at Rs 1731 crore versus Rs 1553.50 crore. Operating profit is likely to go up at Rs 271.80 crore from Rs 190.8 crore. OPM is expected to be at 15.5% versus 12.06%.
Factors to watch
Absence of any blockbuster product in US will keep overall growth modest
Sales growth on account of growth in branded formulations in export markets like Latin America and middle east ie. the semi regulated markets
Will report Lower other income mainly due to translation losses on FCCB (earlier due to rupee appreciation was reporting gains on MTM FCCB)
EBIDTA margin is likely to increase due to low base and favorable sales mix and increased branded formulation exports
By CNBC-TV18's research analyst, Archi Damania
